Caredx Inc Cmn (CDNA) 3.76 $CDNA CareDx Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Caredx Inc Cmn (CDNA) 3.76 $CDNA

CareDx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Sep 21, 8:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of its common stock. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)

CareDx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Sep 20, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CareDx also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)

CareDx Reports Status of Form 10-Q
GlobeNewswire - Tue Aug 16, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it filed with the Securities and Exchange Commission (SEC) a Form 12b-25 for an extension of time for the filing of its Quarterly Report on Form 10-Q. The Company requested the extension because it needs additional time to complete the final review of its financial statements and other disclosures in the Form 10-Q, namely in light of the Company's recent acquisition of Allenex AB and the requirement to include Allenex AB's results in the Company's consolidated financial statements for the first time. Pursuant to SEC regulations, the Company has until Monday, August 22, 2016 to timely file its Form 10-Q, and the Company anticipates that it will file its Form 10-Q by that date. However, because the review is ongoing, no assurances can be given as to the definitive date on which the Form 10-Q will be filed.
CDNA: 3.76 (-0.06)

CareDx Reports Preliminary Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the second quarter ended June 30, 2016.
CDNA: 3.76 (-0.06)

Healthcare Stocks' Q2 Earnings on Aug 10: QHC, CDNA & CGIX
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 6:52AM CDT
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 10.
CDNA: 3.76 (-0.06), QHC: 6.28 (+0.03), CGIX: 1.76 (-0.06)

CareDx Presents Validation of AlloSure(R) at AACC Conference Session on Emerging Topics in Laboratory Medicine
GlobeNewswire - Thu Aug 04, 3:58PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, presented on the analytical validation of AlloSure at the 68 American Conference on Clinical Chemistry (AACC) in Philadelphia, PA. The CareDx abstract at AACC was one of 22 selected for an oral presentation from over 800 submitted abstracts.
CDNA: 3.76 (-0.06)

Teladoc (TDOC) Q2 Loss Narrower Than Expected, Gives View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:04AM CDT
Teladoc (TDOC) incurred loss in the quarter due to an increase in cost of advertising in its direct-to-consumer segment.
TDOC: 18.64 (-0.31), ABCO: 43.58 (-0.60), CDNA: 3.76 (-0.06), AHS: 33.20 (-1.38)

CareDx Supports FDA Development of Next Generation Sequencing Guidelines, Offers Further Perspective on Clinical Grade Quality and Data
GlobeNewswire - Mon Aug 01, 3:05PM CDT
CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, commends the FDA on the release of two draft guidance documents on the standards and the use of public databases for variant detection for Next Generation Sequencing (NGS). Both documents were further supported through a hosted webinar on July 27.
CDNA: 3.76 (-0.06)

CareDx to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 10, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the second quarter 2016 after the market closes on Wednesday, August 10, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
CDNA: 3.76 (-0.06)

AlloSure(TM) Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
GlobeNewswire - Mon Jun 13, 6:30AM CDT
CareDx at the Forefront of Personalized Medicine in Transplantation
CDNA: 3.76 (-0.06)

CareDx (CDNA) Looks Good: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:40AM CDT
CareDx, Inc. (CDNA) saw its shares almost 6% in the last trading session.
AIRM: 32.45 (-0.68), CDNA: 3.76 (-0.06)

CareDx to Host Call to Provide First Analysis of Data from DART Study
GlobeNewswire - Mon Jun 06, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will host a conference call on June 13, 2016 at 4:00 pm ET to provide initial results from the company's DART study.
CDNA: 3.76 (-0.06)

CareDx to Present at 2016 Jefferies Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, CareDx President & Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be presenting and available for meetings at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 4:30pm ET.
CDNA: 3.76 (-0.06)

CareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced it has signed a memorandum of understanding to collaborate with QIAGEN, the leading provider of Sample to Insight solutions for the life sciences and diagnostics industry.
CDNA: 3.76 (-0.06)

CareDx Announces Completion of Enrollment in Multicenter Kidney Transplant Study to Validate Cell-Free DNA Technology
GlobeNewswire - Fri May 27, 3:05PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that the DART study has reached its enrollment goal.
CDNA: 3.76 (-0.06)

CareDx, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Fri May 06, 6:30AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2016.
CDNA: 3.76 (-0.06)

CareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap(R) & AlloSure(TM) in heart transplant patients
GlobeNewswire - Thu Apr 28, 3:52PM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced clinical presentations for the 36 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) being held April 27 - 30, 2016 in Washington, DC.
CDNA: 3.76 (-0.06)

CareDx to Announce First Quarter 2016 Financial Results and Host Conference Call on May 6, 2016
GlobeNewswire - Tue Apr 26, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the first quarter 2016 before the market opens on Friday, May 6, 2016. The Company will host a corresponding conference call beginning at 5:30am PT/8:30am ET.
CDNA: 3.76 (-0.06)

CareDx Completes Allenex Acquisition
GlobeNewswire - Thu Apr 14, 3:15PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the completion of its previously announced acquisition of Allenex AB.
CDNA: 3.76 (-0.06)

CareDx Announces $22 Million Private Placement
GlobeNewswire - Thu Apr 14, 3:14PM CDT
CareDx, Inc. (NASDAQ:CDNA) ("CareDx" or the "Company", a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that it has entered into an agreement to sell approximately 592,000 units in a private placement to be issued by CareDx, for aggregate proceeds in the amount of approximately $14.1 million plus an additional $8 million to be reserved for future investment by certain shareholders. The units were sold to selected institutional and accredited investors and included new shareholders as well as significant participation by current shareholders of CareDx.
CDNA: 3.76 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 110

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 108

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading

Top 5 Most Recently Viewed Articles

McDonald's Earnings Anticipation: Insights from Analysts Ahead

Updated Category News Views 110

Anticipating McDonald's Q3 Earnings Report As the third quarter approaches, McDonald's Corporation (NYSE: MCD) is preparing to unveil its earnings report, sparking interest among investors and analysts alike. This significant event is anticipated to occur just before the opening bell, offering crucial insights into the company's financial health and market position. What...

Continue Reading
BC Platforms Unveils Game-Changing AI Technology for Researchers

Updated Category News Views 281

BC Platforms Introduces BC Catalyst for Precision Medicine BC Platforms has officially launched BC Catalyst, an innovative AI-native analytics product designed to enhance precision medicine. This breakthrough technology integrates genomic and real-world data, allowing for actionable insights throughout the entire drug lifecycle. With BC Catalyst, the company aims to...

Continue Reading
TestFly Expands QA Testing Services with Red Cerberus Deal

Updated Category News Views 300

TestFly Enhances Service Offerings Through Acquisition TestFly, a prominent provider of innovative quality assurance testing solutions for the video game and mobile gaming sectors, has undertaken a significant move by acquiring Red Cerberus. This acquisition is set to transform the landscape of video game quality assurance by integrating Red Cerberus' expertise and...

Continue Reading
Unveiling Insurance Industry Abuses: New Podcast Series Launch

Updated Category News Views 173

Consumer Watchdog Introduces Insightful Podcast Series Smoke & Mirrors Debuts Today, Investigating Insurance Underpayments and Consumer Resilience Today marks the launch of a groundbreaking podcast series from Consumer Watchdog, titled "Smoke & Mirrors: Investigating Home Insurance Abuses," aimed at shedding light on the troubling practices that major insurance firms...

Continue Reading
MongoDB’s Leadership Change: Opportunities for Investors Ahead

Updated Category News Views 171

Understanding the Leadership Shift at MongoDB Recently, MongoDB (NASDAQ: MDB) has been a significant topic of discussion in investing circles due to its remarkable stock performance. After the stock's impressive rise from $188.81 to about $358 per share, many are questioning the right strategy—should investors lock in their profits now or remain committed for the long...

Continue Reading